Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules December 18, 2008
Ligand Presents Positive LGD-4665 Clinical Trial Results at the American Society of Hematology Annual Meeting December 8, 2008
Ligand Pharmaceuticals and the SALK Institute Enter Settlement Agreement and Mutual Release of All Claims September 5, 2008
Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for PROMACTA(R) NDA June 20, 2008